Most technology transfer offices (TTOs), especially in the United States, are internal administrative units of the university itself — a department that reports through the vice president for research, subject to the same procurement, hiring, and public-institution rules as the rest of the campus. Israel’s four largest research universities do something structurally different: each channels essentially all of its invention disclosure, patenting, licensing, and startup-equity activity through a separate, wholly-owned for-profit company. Hebrew University of Jerusalem uses Yissum, the Weizmann Institute of Science uses Yeda, Tel Aviv University uses Ramot, and the Technion – Israel Institute of Technology operates its commercialization activity through T3 (Technion Technology Transfer) under the Technion Research and Development Foundation (TRDF). This “subsidiary company” model is one of the oldest and most consistently used technology-transfer structures in the world, predating Bayh-Dole in the United States by more than a decade, and it remains the default organizational pattern across nearly every major Israeli research university today.
For research administrators comparing institutional models — or advising an Israeli partner institution, licensee, or investor — understanding this structure matters because it changes who actually holds the IP, who signs a license agreement, and how equity in a spinout is allocated. This guide covers each of the four flagship companies, why the subsidiary-company structure exists, how it differs from the internal-office model most U.S. and many European universities use, and what it means in practice for licensing and spinout formation.
The Israeli Model: A Separate For-Profit Company, Not an Internal Office
In the internal-TLO model, the university itself owns the IP its researchers generate, and a department within the university administration (subject to university HR, procurement, and governance rules) manages disclosure intake, patenting, and licensing. In the Israeli subsidiary-company model, the university instead assigns commercialization rights to a separate, arm’s-length company that it wholly owns. That company — not the university directly — typically holds or manages the IP, negotiates and signs license agreements, takes equity in spinout companies, and distributes net income back to the university (and, under each institution’s own inventor-sharing policy, to the inventors) according to a defined revenue-sharing formula.
The pattern is consistent across Israel’s research universities:
- Yissum Research Development Company Ltd. — Hebrew University of Jerusalem
- Yeda Research and Development Co. Ltd. — Weizmann Institute of Science
- Ramot at Tel Aviv University Ltd. — Tel Aviv University
- T3 (Technion Technology Transfer), operating under the Technion Research and Development Foundation — Technion – Israel Institute of Technology
- BGN Technologies Ltd. — Ben-Gurion University of the Negev
- BIRAD Research and Development Company — Bar-Ilan University
Each of the smaller companies follows the same basic template as the four flagship organizations profiled below: a dedicated corporate entity, wholly owned by its parent university, whose sole function is commercializing that university’s research.
Yissum — Hebrew University of Jerusalem
Yissum was established in 1964 to protect and commercialize intellectual property generated by Hebrew University researchers, and is widely reported to be the oldest university technology-transfer company in Israel and among the oldest in the world. Hebrew University assigns commercialization rights in its researchers’ inventions to Yissum, which handles patenting, licensing, and startup formation on the university’s behalf and returns net proceeds to the university under its inventor and institutional revenue-sharing policy. Yissum has been involved in the formation of dozens of spinout companies over its history, including several that reached public markets or large acquisitions — Mobileye, OrCam, and ExLibris are commonly cited examples — alongside a large ongoing licensing portfolio.
Yeda — Weizmann Institute of Science
Yeda Research and Development Co. Ltd. (“yeda” is Hebrew for “knowledge”) was established in 1959 as the commercial arm of the Weizmann Institute of Science, making it one of the earliest examples of this model anywhere — commonly described as the second dedicated university technology-transfer company established in the world. Yeda holds an exclusive agreement with the Weizmann Institute to market and commercialize the Institute’s intellectual property, generating income that supports further research and education at Weizmann. Yeda’s best-known licensing outcome is glatiramer acetate, a multiple sclerosis therapy discovered at Weizmann and licensed to Teva Pharmaceutical Industries, later marketed as Copaxone.
Ramot — Tel Aviv University
Ramot at Tel Aviv University Ltd. was founded in 1973 and is fully owned by Tel Aviv University. Like Yissum and Yeda, Ramot owns and manages the intellectual property created by its parent university’s researchers and is responsible for evaluating disclosures, filing and prosecuting patents, negotiating licenses, and supporting spinout formation, working directly with researchers, entrepreneurs, and outside companies to move Tel Aviv University technology into commercial use.
T3 / Technion Research and Development Foundation — Technion
The Technion – Israel Institute of Technology’s commercialization activity runs through T3 (Technion Technology Transfer), which operates under the Technion Research and Development Foundation (TRDF). TRDF is the legal entity that holds and licenses Technion-originated IP and invests in early-stage spinoff companies built on Technion technology; T3 is the operating team that manages invention disclosure, patent prosecution, licensing negotiations, and new-company formation on TRDF’s behalf, supporting roughly a dozen or more new startups a year on average. The Technion’s commercialization track record includes companies such as Mazor Robotics, Pluristem, and ReWalk, several of which reached public markets.
Why This Structure Exists
None of these four companies was created recently — Yeda (1959), Yissum (1964), and Ramot (1973) all predate the U.S. Bayh-Dole Act (1980) by years or decades, so the Israeli model was not built as a response to, or a variant of, Bayh-Dole; it developed independently and earlier. The consistent rationale cited across technology-transfer practice for using a separate corporate entity, rather than an internal university department, is largely structural and commercial rather than legal in the Bayh-Dole sense:
- Commercial flexibility. A for-profit company can negotiate license terms, hold and vote equity in a spinout, sit on a spinout’s board, and hire staff on commercial (not civil-service or public-university) compensation terms — all of which are typically harder for a university’s own internal administrative structure to do directly.
- Liability and governance separation. Housing commercial licensing and equity activity in a separate legal entity keeps that activity, and its associated risk, at arm’s length from the university’s core academic and public-institution governance.
- A single, focused commercialization function. Because the subsidiary company exists for exactly one purpose, its staff, incentive structures, and decision processes can be built specifically around technology transfer rather than layered onto a general university administrative unit.
This is the same underlying logic that leads some U.S. and European universities to spin out a nonprofit or for-profit foundation for technology transfer (the Wisconsin Alumni Research Foundation being a well-known long-standing U.S. example), but in Israel it became the default model across the research-university sector rather than the exception.
How It Differs From the U.S. Internal-TLO Model
The U.S. model, shaped heavily by the Bayh-Dole Act, generally has the university itself elect title to inventions made with federal funding and manage disclosure, patenting, and licensing through an internal office bound by the university’s own procurement and conflict-of-interest policies (see CASRAI’s guide to Bayh-Dole march-in rights and university tech transfer and to the underlying 37 CFR 401 implementing regulations for how that obligation works in practice). The IP owner of record, the licensor on any resulting agreement, and the university are typically the same legal entity.
In the Israeli model, by contrast:
- Ownership and contracting party differ from the university. A license agreement is typically between the licensee and Yissum/Yeda/Ramot/TRDF, not directly between the licensee and the university, even though the underlying research was performed at the university.
- Equity and board seats sit with the subsidiary, not a university office. When a spinout is formed, the subsidiary company — not an internal university committee — typically negotiates and holds the university’s equity stake and represents that interest on the company’s board.
- Revenue flows back through a defined corporate relationship. Net income the subsidiary earns from licensing and equity events is distributed to the university (and to inventors, per each institution’s revenue-sharing policy) as a contractual and governance matter between the company and its university owner, rather than an internal budget transfer within one institution.
Functionally, both models perform the same core tasks — disclosure intake, patentability assessment, licensing, spinout support — described generically in CASRAI’s guide to university spinout companies. The difference is almost entirely organizational and legal-entity structure, not the substance of the work.
Practical Implications: Equity, Spinout Formation, and Licensing
For anyone negotiating with, licensing from, or partnering with an Israeli university, a few practical consequences follow directly from the subsidiary-company structure:
- Confirm the correct contracting entity. A term sheet or license agreement involving Hebrew University research should generally run through Yissum, not the university directly — and equivalently for Yeda/Weizmann, Ramot/Tel Aviv University, and T3-TRDF/Technion. Using the wrong named party is a common and avoidable drafting error.
- Equity stakes are negotiated by the subsidiary. When founding a spinout around licensed university IP, the initial equity split (see CASRAI’s guide to university spinout equity splits) is negotiated with Yissum/Yeda/Ramot/TRDF as the counterparty representing the university’s ownership interest, not with a university department.
- Faculty conflict-of-interest review still applies. A faculty inventor who becomes a founder, officer, or significant equity holder in a spinout still needs disclosure and management under the university’s own conflict-of-interest process, independent of which entity holds the licensed IP — the general principles in CASRAI’s guide to faculty conflict of interest in startups apply regardless of the subsidiary-company structure.
- Revenue-sharing terms are set by the subsidiary’s own policy, not a single national standard. Each of Yissum, Yeda, Ramot, and TRDF operates its own inventor revenue-sharing formula; there is no single Israel-wide statutory revenue split equivalent to a Bayh-Dole provision, so terms should be confirmed with the specific subsidiary company rather than assumed to match another Israeli institution.
Frequently Asked Questions
Is Yissum a part of Hebrew University, or a separate company?
Yissum is a separate, wholly-owned for-profit company. Hebrew University assigns commercialization rights in its researchers’ inventions to Yissum, which then manages patenting, licensing, and spinout formation and returns net proceeds to the university.
Does every Israeli university use this subsidiary-company model?
The pattern is widespread across Israel’s major research universities — Hebrew University (Yissum), Weizmann Institute (Yeda), Tel Aviv University (Ramot), Technion (T3/TRDF), Ben-Gurion University (BGN Technologies), and Bar-Ilan University (BIRAD) all use a dedicated, wholly-owned corporate entity rather than a purely internal office.
Which came first, Yeda or Yissum?
Yeda (Weizmann Institute), established in 1959, predates Yissum (Hebrew University), established in 1964, by five years. Both predate Ramot (Tel Aviv University, 1973) and all three predate the U.S. Bayh-Dole Act (1980).
Who actually owns the patents on an invention from an Israeli university lab?
In this model, the subsidiary company — not the university itself — typically holds or manages the patent rights on behalf of the university, under the assignment or exclusive-agency agreement between the university and its subsidiary. The specific legal mechanism (assignment versus exclusive marketing agreement) varies by institution, so the governing agreement for the specific university involved should be confirmed rather than assumed.
Do licensees or investors deal with the university or the subsidiary company?
Licensees and investors typically deal directly with the subsidiary company (Yissum, Yeda, Ramot, or T3/TRDF), since that is the entity that holds the relevant rights, negotiates terms, and signs the resulting agreement, even though the underlying research and researchers are based at the university.
For more on how the pieces of a technology-transfer operation fit together generally, see CASRAI’s technology transfer pillar page, or compare this model against Germany’s applied-research structure in CASRAI’s guide to the Fraunhofer-Gesellschaft model.
